Secondary Obliteration of Old Radical Cavities Using S53P4 Bioactive Glass

Sponsor
Diakonessenhuis, Utrecht (Other)
Overall Status
Recruiting
CT.gov ID
NCT06116513
Collaborator
(none)
97
1
36
2.7

Study Details

Study Description

Brief Summary

In canal wall down surgeries, the posterior bony wall of the external auditory canal (EAC) is removed to increase exposure. The creation of a so-called radical cavity comes with several possible disadvantages, such as higher rates of postoperative otorrhea and purulence, pain, adherence to water precautions and dizziness. Secondary obliteration of the mastoid cavity and reconstruction of the posterior wall of the EAC can help alleviate these symptoms. Our goal is to study the efficacy of secondary obliteration using S53P4 bioactive glass as obliteration material. This bioactive glass has several important characteristics, such as retaining of volume over time and antibacterial effects. The main outcome will be postoperative otorrhea as indicated by the Merchant grading scale.

Condition or Disease Intervention/Treatment Phase
  • Device: S53P4 bioactive glass granules

Study Design

Study Type:
Observational
Anticipated Enrollment :
97 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Efficacy of Secondary Obliteration of Chronically Discharging Old Radical Cavities Using S53P4 Bioactive Glass
Actual Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients with old troublesome radical cavities

These patients would have old Canal Wall Down cavities that were troublesome

Device: S53P4 bioactive glass granules
During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.

Outcome Measures

Primary Outcome Measures

  1. Number or participants with a dry ear pre- and postoperatively [At 1, 3 and 5-year postoperatively.]

    Postoperative otorrhea as indicated by the Merchant grading system. Grade 0-1 was defined as control of infection and grade 2-3 was defined as failure.

Secondary Outcome Measures

  1. Pre- and postoperative air conduction [pre-operatively, in the first 6 months following surgery and 6-12 months postoperatively]

    Audiological outcomes pre-operatively, compared to early postoperatively (<6months) and late postoperatively (>6months). Evaluated in the audiometry is the air conduction in decibel.

  2. Pre- and postoperative air-bone gap [pre-operatively, in the first 6 months following surgery and 6-12 months postoperatively]

    Audiological outcomes pre-operatively, compared to early postoperatively (<6months) and late postoperatively (>6months). Evaluated in the audiometry is the air-bone gap in decibel.

  3. The number of patients with postoperative surgical complications [First year following surgery]

    Complications that occured within the first year following surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Old canal wall down cavity

  • Operated between 2011 and 2022

Exclusion Criteria:
  • Middle ear cholesteatoma

  • Previous obliteration

Contacts and Locations

Locations

Site City State Country Postal Code
1 Diakonessenhuis Utrecht Netherlands 3582KE

Sponsors and Collaborators

  • Diakonessenhuis, Utrecht

Investigators

  • Principal Investigator: J.J. Quak, MD, PhD, Diakonessenhuis, Utrecht

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Diakonessenhuis, Utrecht
ClinicalTrials.gov Identifier:
NCT06116513
Other Study ID Numbers:
  • 16-004-1
First Posted:
Nov 3, 2023
Last Update Posted:
Nov 3, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Nov 3, 2023